Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer

Area of Science:

• Oncology
• Immunology
• Vascular Biology

Background:

• Advanced kidney cancer treatments have improved, but novel strategies are needed to enhance patient outcomes.
• Current therapies include targeted agents and immune-based treatments, with potential for synergistic combinations.
• Combined inhibition of vascular endothelial growth factor (VEGF) and programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) pathways is a promising strategy.

Purpose of the Study:

• To describe the development and clinical evaluation of VEGF and PD-1/PD-L1 inhibitors.
• To present preclinical evidence supporting the rationale for combined pathway blockade.
• To explore the potential of combined VEGF and PD-1/PD-L1 blockade in advanced kidney cancer.

Main Methods:

• Development and clinical evaluation of VEGF inhibitors.
• Development and clinical evaluation of PD-1/PD-L1 inhibitors.
• Preclinical studies investigating pathway interactions and combined blockade efficacy.

Main Results:

• Preclinical data suggest interaction between VEGF and PD-1/PD-L1 pathways.
• VEGF blockade may reduce immune tolerance and enhance PD-1/PD-L1 blockade efficacy.
• Early clinical trials show encouraging antitumor activity with combined VEGF and PD-1/PD-L1 blockade.

Conclusions:

• Combined VEGF and PD-1/PD-L1 blockade is a viable strategy for advanced kidney cancer.
• This approach demonstrates encouraging antitumor activity in early trials.
• Further research is needed to optimize this combination therapy and its application.